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Abstract
Aims/hypothesis In obesity, beta cells activate compensatory
mechanisms to adapt to the higher insulin demand.
Interleukin-1 receptor antagonist (IL-1Ra) prevents obesity-
induced hyperglycaemia and is a potent target for the
treatment of diabetes, but the mechanisms of its secretion
and regulation in obesity are unknown. In the present study,
we hypothesise the regulation of IL-1Ra secretion by
purinergic P2X7 receptors in islets.
Methods Production and regulation of P2X7 werestudied in
pancreatic sections from lean and obese diabetic patients,
non-diabetic controls and in isolated islets. IL-1Ra, IL-1β
and insulin secretion, glucose tolerance and beta cell mass
werestudiedinP2x7 (also known as P2Rx7)-knockout mice.
Results P2X7 levels were elevated in beta cells of obese
patients, but downregulated in patients with type 2 diabetes
mellitus. Elevated glucose and non-esterified fatty acids
rapidly activated P2X7 and IL-1Ra secretion in human
islets, and this was inhibited by P2X7 blockade. In line with
ourresultsinvitro,P2x7-knockout mice had a lower capacity
to secrete IL-1Ra. They exhibited severe and rapid hyper-
glycaemia, glucose intolerance and impaired beta cell
function in response to a high-fat/high-sucrose diet, were
unable to compensate by increasing their beta cell mass in
response to the diet and showed increased beta cell apoptosis.
Conclusions/interpretation Our study shows a tight correla-
tion of P2X7 activation, IL-1Ra secretion and regulation of
beta cell mass and function. The increase in P2X7 production
is one mechanism that may explain how beta cells compen-
sate by adapting to the higher insulin demand. Disturbances
within that system may result in the progression of diabetes.
Keywords Diabetes.Interleukin-1receptorantagonist.
Islets.Obesity.PurinergicreceptorP2X7
Abbreviations
BzATP Benzoyl ATP
GSIS Glucose-stimulated insulin secretion
HFD High-fat/high-sucrose diet
IL-1 Interleukin-1
IL-1Ra Interleukin-1 receptor antagonist
IPGTT Intraperitoneal glucose tolerance test
IPITT Intraperitoneal insulin tolerance test
ND Normal diet
P2X7-KO P2x7 knockout
P2X7 P2X7 receptor
WT Wild-type
Introduction
An alarming increase in obesity and type 2 diabetes
mellitus has been recorded among the global population.
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Chicago, IL, USAThe rise in type 2 diabetes is tightly connected with a
dramatic increase in obesity, a major risk factor for the
development of type 2 diabetes [1]. Most obese people
have become insulin resistant but compensate for the
enhanced insulin demand by increasing insulin secretion
[2]. In order to explore how beta cells increase mass under
physiological conditions, it is important to stimulate beta
cell expansion in vivo and in vitro. The pathology of type 2
diabetes comprises initial hyperinsulinaemia with, there-
after, a continuous decline in beta cell function in
association with a progressive decrease in beta cell mass
due to an increasing rate of beta cell apoptosis [3]. A
previously described mechanism for glucose-induced beta
cell apoptosis involves the production and secretion of
interleukin-1β (IL-1β) by the beta cell itself [4], which is
blocked by an anti-inflammatory cytokine and naturally
occurring antagonist of interleukin-1α (IL-1α) and β [5–7],
the interleukin-1 receptor antagonist (IL-1Ra) [8]. Similarly
to IL-1β, IL-1Ra binds to type 1 and 2 IL-1 receptors
(IL-1R1, IL-1R2), but lacks a second binding domain.
IL-1Ra does not recruit the IL-1 receptor accessory
protein, the second component of the receptor complex,
and blocks IL-1R1 signalling. Endogenous production
and secretion of IL-1Ra has been shown to limit
inflammation and tissue damage.
Exogenous IL-1Ra protects against IL-1β-induced beta
cell damage [9, 10], counteracts low-dose-streptozotocin-
induced diabetes [11] and autoimmune diabetes [12].
Results from a clinical study show that IL-1Ra improves
glycaemic control and beta cell function in patients with
type 2 diabetes [13].
The secretory mechanisms and those regulating changes
of IL-1Ra are unknown. An increasing body of evidence
suggests that IL-1β, as well as intracellular IL-1Ra, is
secreted by a leaderless pathway via activation of the P2X7
receptor (P2X7;[ 14]). P2X7, a member of the purinergic
receptor family, is a G-protein-coupled ionotropic receptor
for extracellular ATP that forms a pore in response to ligand
stimulation, regulating cell permeability, cytokine release
and apoptosis [15]. The cytokine IL-1β, which lacks a
leader signal sequence, does not follow the classic
endoplasmic-reticulum-to-Golgi pathway of secretion. Its
secretion is governed by P2X7-mediated pathways [16, 17].
This raises a question about the mechanisms of its release;
it has been demonstrated that it is secreted upon activation
of P2X7 receptors, leading to shedding of microvesicles that
contain the cytokine [18].
The pore-forming ATP receptor P2X7 is also responsible
for IL-1Ra release in endothelial cells and macrophages
[14]. Consequently, we hypothesised that P2X7 could be
involved in IL-1Ra releasei nb e t ac e l l s .T h ew o r k
presented here evaluates an important role for P2X7 in beta
cells, not only for cytokine release but also for insulin
release and apoptosis. We have found upregulation of P2X7
in islets from obese individuals, while receptors were
almost undetectable in type 2 diabetes. We then investigated
whether P2X7 is involved in the compensatory mechanisms
of the beta cells in response to an increased insulin demand
in insulin resistance.
Methods
Animals P2x7 ( a l s ok n o w na sP2rx7)-knockout mice
(B6.129P2-P2rx7
tm1Gab/J; P2X7-KO) backcrossed to
C57BL/6 mice for ten generations and C57BL/6 J wild-
type (WT) mice were obtained from Jackson Laboratories
(Bar Harbor, ME, USA) at 4 weeks of age. Beginning at
5 weeks of age and continuing for 16 weeks, knockout as
well as wild-type animals were fed a normal diet (ND;
P2X7-KO-ND and WT-ND, respectively; normal diet was
Harlan Teklad Rodent Diet 8604, containing 12.2, 57.6 and
30.2% energy from fat, carbohydrate and protein, respec-
tively) or a high-fat/high-sucrose diet (HFD; P2X7-KO-
HFD and WT-HFD; high-fat/high-sucrose diet was Surwit
diet, Research Diets, New Brunswick, NJ, USA containing
58, 26 and 16% energy from fat, carbohydrate and protein,
respectively [19]). Further details are described in the
Electronic supplementary material (ESM).
Intraperitoneal glucose and insulin tolerance tests At the
beginning of the experiment and after 4, 8, 12 and 16 weeks
of diet, all animals underwent in vivo studies. For
intraperitoneal glucose tolerance tests (IPGTTs), glucose
at a dose of 1 g/kg body weight and for intraperitoneal
insulin tolerance tests (IPITTs), recombinant human
insulin (Novolin; Novo Nordisk, Bagsværd, Denmark) at
a dose of 0.5 U/kg was injected intraperitoneally as
described before [9].
Islet isolation and culture After 12 and 16 weeks of diet
and treatment, mice were killed, blood was taken by
cardiac puncture and serum stored at −80°C until further
analysis. Thereafter, islets from all groups were isolated
as described previously [20]. Human islets were isolated
from pancreases of six healthy organ donors as described
previously [21]. Mouse islets were cultured in RPMI-1640
medium (11.1 mmol/l glucose), and human islets in
CMRL-1066 medium (5.5 mmol/l glucose), as described
previously [22].
Functional analysis of P2X7 in human islets Freshly
isolated human islets were grown on dishes coated with
extracellular matrix until a monolayer formed. Cells were
loaded with 10 μmol/l YO-PRO-1 (0.375 kDa; Molecular
Probes/Invitrogen, Carlsbad, CA, USA) in PBS after a
1580 Diabetologia (2009) 52:1579–1588protocol by Narcisse et al. [15]. Further details are
described in the ESM.
Glucose-stimulated insulin secretion Islets used to perform
glucose-stimulated insulin secretion (GSIS) experiments
were kept in culture medium for 24 h and GSIS was
performed as described previously [9]. Islets were
extracted with 0.18 mol/l HCl in 70% (vol./vol.) ethanol
for determination of insulin content. Islet insulin was
determined using mouse or human insulin ELISA (ALPCO,
Salem, NH, USA).
IL-1Ra and IL-1β analysis Serum obtained from retro-
orbital bleedings and cell culture supernatant fractions from
mouse isolated islets were evaluated using mouse IL-1Ra or
IL-1β Quantikine ELISA (R&D Systems, Minneapolis,
MN, USA) (see ESM).
Beta cell mass and histochemical analyses After 12 weeks
of diet and treatment, pancreases were weighed and fixed
overnight in 4% (vol./vol.) paraformaldehyde at 4°C under
continuous shaking followed by paraffin embedding,
orienting pancreases such that sections were cut along the
head–tail axis. Beta cell mass and apoptosis were analysed
as described previously [8] (P2X7 staining is described in
the ESM). Human pancreatic tissue was obtained at autopsy
from non-diabetic individuals and from people with type 2
diabetes (all with documented fasting plasma glucose
>8.048 mmol/l). ESM Table 1 summarises age, BMI, sex,
glucose levels and diagnosis.
RNA extraction and PCR analysis ThetotalRNAofisolated
islets was extracted after overnight culture as described
previously [8]. The primers were: P2X7 5′AGATCGTGGA
GAATGGAGTG3/5′TCTCGTGGTGTAGTTGTGG3′;
tubulin 5′TCCACGTTGGCCAGGCTGGTGTCCAG3′/5′
CTGTGATGAGCTGCTCA GGGTGG3′.
Western blot analysis Islet lysates were prepared from 100
islets per treatment condition as described previously [23].
PVDF filters (Amersham Biosciences/GE Healthcare,
Uppsala, Sweden) were incubated with rabbit anti-P2X7
(Almone Labs, Jerusalem, Israel), rabbit-anti-IL-1Ra (R&D
Systems) and anti-actin (#4967; Cell Signaling Technology,
Beverly, MA, USA), followed by incubation with
horseradish-peroxidase-linked anti-rabbit IgG.
Statistical analysis Samples were evaluated in a randomised
manner by two investigators (R. Glas and K. Maedler) who
were blinded to the treatment conditions. Data are presented
as means±SE and were analysed by paired Student’s t test
or by analysis of variance with a Bonferroni correction for
multiple group comparisons.
Results
P2X7 is produced in beta cells, upregulated in obesity and
decreased in diabetes To investigate the role of P2X7 in
islets, we analysed its production in isolated human islets.
The presence of P2X7 transcripts is shown by mRNA
analysis (Fig. 1a) and western blotting (Fig. 1b). The
majority of the beta cells stained positive for P2X7
(Fig. 1c). We also found the presence of P2X7 in alpha
cells (not shown). To analyse regulation of P2X7 in vivo,
we compared staining and production of P2X7 in beta cells
in pancreatic sections obtained at autopsy from both obese
P2X7
Tubulin P2X7
68 kDa
a
c
d
Merge Insulin
b
RT– RT+
P2X7
P2X7
Insulin Merge
Fig. 1 P2X7 is produced in beta cells, upregulated in obesity and
decreased in diabetes. a Agarose gel of the PCR products P2X7 and
tubulin obtained using cDNA from isolated human islets that was
pretested for insulin production; mRNA served as a negative control
(−). RT, reverse transcriptase. b Western blot to detect P2X7 in human
islets. c Immunofluorescence to detect P2X7 and insulin in human
pancreatic islets cultured for 24 h at 5.5 mmol/l glucose. P2X7 is
shown in red and insulin, a marker for beta cells, in green. Co-
localisation (‘Merge’) is visible as yellow. The results are represen-
tative of at least three independent experiments using islets from three
donors. d Paraffin-embedded human pancreatic sections from a lean
non-diabetic control (first row), an obese control (second row), a lean
patient with type 2 diabetes (third row) and an obese patient with
type 2 diabetes (fourth row) were analysed for the presence of P2X7
(shown in red) and insulin (green). Co-localisation is visible in yellow.
The results represent five independent cases from each group
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diabetes. Double immunostaining for P2X7 and insulin
(Fig. 1d) confirmed the presence of P2X7 localised in the
beta cells in human pancreatic sections from lean control
patients (first row), which was highly upregulated in obese
non-diabetic patients (second row). In contrast, in both lean
(third row) and obese (fourth row) diabetic groups, P2X7
was barely detectable; no islet P2X7 receptors were found
in any of the diabetic pancreases.
P2X7 is upregulated by short-term exposure to elevated
glucose and NEFA in isolated human islets The functional
productionofP2X7 in beta cells was verified with the nucleic
acid stain YO-PRO-1 (0.375 kDa, Molecular Probes). This is
based on the pore-forming character of P2X7; its activation
leads to the formation of a pore that is passable to molecules
up to 0.9 kDa [24]. YO-PRO-1 has been widely used to
visualise P2X7 activity [15], although YO-PRO-1 can also
access the beta cell in the presence of membrane blebbing
during apoptosis and is also used for the detection of
apoptotic cells [25]. Freshly isolated human islets plated on
dishes coated with extracellular matrix were loaded with
10 μmol/l YO-PRO-1 10 min before receptor activation by
addition of 100 μmol/l benzoyl ATP (BzATP). Within 5 min
of exposure, YO-PRO-1 was taken up by 45±6.01% of the
islet cells; this was inhibited by pre-incubation with the
specific P2X7 inhibitor KN-62, which has been demonstrated
to block YO-PRO-1 uptake initiated by prolonged P2X7
activation previously [26]. The ATP-degrading enzyme
apyrase (a less specific inhibitor of P2X7) had similar effects
on YO-PRO-1 uptake (Fig. 2a). These data show production
of functional P2X7 in islets. In contrast, <5% of the untreated
cells showed YO-PRO-1 uptake.
As we have observed changes in P2X7 levels in obesity
and diabetes, we tested whether P2X7 is activated by a
diabetic milieu in culture. Islets were exposed to increased
glucose concentrations (5.5–33.3 mmol/l, Fig. 2b,c) or
0.5 mmol/l palmitic acid (Fig. 2d) for 10 min after YO-
PRO-1 loading. Elevated glucose concentration activated
P2X7, as did palmitic acid; we observed a nine-fold
activation by 33.3 mmol/l glucose, six-fold activation by
11.1 mmol/l glucose and a nine-fold activation by palmitic
acid within 5 to 10 min of exposure (p<0.001). Peak levels
slightly decreased after 15 min exposure, but remained
elevated compared with control conditions throughout the
1 h incubation period, similar to the finding with BzATP
stimulation. In all assays, co-culture with the P2X7
inhibitors KN-62 (Fig. 2a–d) and apyrase (Fig. 2a, b, d),
reduced the P2X7 activation induced by BzATP, elevated
glucose or palmitic acid.
As BzATP evokes P2X7 effects very briefly, even within
1t o3 0s[ 27], we wanted to see if there is a change in P2X7
level in response to the activation. Elevated glucose
concentrations increased P2X7 mRNA levels (Fig. 2e:
1.7-fold increase with 11.1 mmol/l glucose, 2.5-fold
increase with 33.3 mmol/l glucose and 1.8-fold increase
with palmitic acid, compared with control [untreated, with
5.5 mmol/l glucose], p<0.05) after 10 min of exposure.
This was confirmed by western blot analysis (Fig. 2f, g).
Changes in mRNA level and protein production were
detected within this short time, whereas values returned to
basal after 24 h of exposure (not shown). Previous reports
show that IL-1β induces increases in P2X7 at 6 h, with
levels decreasing after 48 h of treatment [15]. One
explanation for the increase in P2X7 within this narrow
timeframe would be a rapid de novo synthesis of P2X7
mRNA and P2X7 protein, given weight by its relatively
small size (595 amino acids/68 kDa).
Recently, we have shown that IL-1Ra can protect from
impaired beta cell function and death in vivo and in vitro
[4, 8]. The mechanisms of its secretion from the beta cell
are unknown. We tested whether activation of P2X7 leads
to IL-1Ra secretion. Long-term glucose exposure had no
effect on IL-1Ra secretion (data not shown and [28, 29]).
But short-term (30 min) exposure of islets to elevated
glucose, palmitic acid or BzATP induced IL-1Ra secretion,
which was inhibited by KN-62 (Fig. 2h). Analysis of
insulin secretion in the same supernatant fractions showed
similar regulation of insulin secretion. Elevated glucose
levels (11.1 and 33.3 mmol/l), 0.5 mmol/l palmitic acid and
100 μmol/l BzATP induced insulin secretion, which was
prevented by co-culture with KN-62 (Fig. 2i).
Regulation of IL-1Ra production by glucose and palmitic
acid was confirmed by western blot analysis. Short-term
exposureofhumanisletstoelevatedglucose andpalmiticacid
(30 min–8 h) induced IL-1Ra secretion, whereas no differ-
ences were observed at 24 h treatment. These data indicate a
parallel induction of IL-1Ra and P2X7 in pancreatic islets.
P2X7-deficient mice have impaired glucose tolerance, beta
cell mass and function and fail to adapt IL-1Ra secretion
to a high-fat diet The changes in P2X7 activation in human
islets in vitro were compared with glucose tolerance, beta
cell survival and IL-1Ra secretion in the P2X7-KO mice.
Male C57Bl/6 WT and P2X7-KO mice were fed an ND or
an HFD for up to 16 weeks. Mice fed the HFD gained more
weight than the ND control group; this was not influenced
by the P2X7-deficiency (Fig. 3a). Before and throughout
the treatment period, we measured the fasting and fed blood
glucose level every 4 weeks. Average fasted glucose levels
before the beginning of the study in 5-week-old mice were
3.88±0.33 mmol/l in the wild-type mice and 5.27±
0.44 mmol/l in the P2X7-KO mice (p<0.05).
After 12 weeks of the diet, high-fat feeding increased
glucose levels and impaired glucose tolerance. The highest
glucoselevelswerefoundintheP2X7-KO mice fed an HFD,
1582 Diabetologia (2009) 52:1579–1588with differences significant at all time points during an
IPGTT compared with all other groups (WT-ND, WT-HFD,
P2X7-KO-ND; Fig. 3b, p<0.01). Glucose tolerance further
deteriorated after 16 weeks of HFD diet (not shown).
Figure 3c shows serum insulin levels during an IPGTT
after 12 weeks of diet and treatment. As previously
described [30], high-fat feeding resulted in hyperglycaemia
(Fig. 3b) as well as hyperinsulinaemia (Fig. 3c, p<0.001)
compared with control diet mice. Compared with mice
consuming an ND, fasted insulin levels were 3.4-fold
higher in HFD-fed WT mice and 5.7-fold higher in the
P2X7-KO mice (p<0.01). The HFD-fed WT mice had a
much lower capacity to increase their glucose-stimulated
insulin release (Fig. 3d, p<0.01), whereas the P2X7-KO
mice on the HFD completely failed to further increase their
insulin levels in response to a glucose challenge (Fig. 3d,
p<0.001). P2X7-KO-ND mice had a 1.3-fold lower
stimulatory index than the WT control mice (p<0.05).
These data indicate that P2X7-KO mice have an impaired
beta cell function, which deteriorates under the challenge
of an HFD treatment.
To determine insulin sensitivity, we performed insulin
tolerance tests by measuring glucose concentrations after
intraperitoneal insulin injection of 0.5 U/kg body weight.
Glucose levels from all mice were significantly higher at all
time points during the IPITT compared with control wild-
type mice on an ND (unchanged in P2X7-KO-ND at
120 min, Fig. 3e). To investigate whether the impaired
glucose tolerance and insulin secretion was due to a defect
in beta cell survival together with beta cell function, we
analysed beta cell mass from the four groups after 12 and
16 weeks of treatment. As reported previously [8], after
12 weeks of diet, islet beta cell mass was increased by high-
fat feeding in the WT mice compared with those on a
normal diet (1.6-fold increase, p<0.01; Fig. 3f,g). In
contrast, P2X7-KO mice had no such compensatory
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Fig. 2 P2X7 is upregulated by short-term exposure to elevated
glucose and NEFA in human isolated islets. a–d Freshly isolated
human islets were grown on dishes coated with extracellular matrix
until monolayer formation (72 h). Uptake of the nucleic stain YO-
PRO-1 was allowed by inducing P2X7 activation via stimulation with
a 100 μmol/l BzATP (black triangles), b 33.3 mmol/l glucose (black
triangles), c 11.1 mmol/l glucose (black triangles) and d 0.5 mmol/l
palmitate at 5.5 mmol/l glucose (black triangles), respectively, or
inhibited with 30 min pre-incubation with the specific inhibitor of
P2X7, KN-62 (crosses), or apyrase (white squares). As the control,
human islets were incubated in media containing 5.5 mmol/l glucose
(black squares). Quantification was accomplished by verifying YO-
PRO-1 emission at 488 nm and counting fluorescence nuclei per
visual field (four fields per condition) every 5 min for 1 h; n=3
experiments from three different donors. Data are expressed as
percentage of YO-PRO-positive islet cells. e P2X7 mRNA levels
and f, g P2X7 protein levels from human islets in response to
incubation with 11.1 mmol/l or 33.3 mmol/l glucose or palmitate
(NEFA) for 10 min. The results are presented after normalising to
tubulin mRNA levels and as relative numbers to the corresponding
unstimulated control (5.5 mmol/l glucose). Actin was used as loading
control. h IL-1Ra and i insulin secretion from human islets exposed
for 1 h to elevated glucose concentrations or palmitic acid (NEFA) at
5.5 mmol/l glucose with (black bars) or without (white bars) 30 min
pre-treatment with KN-62. IL-1Ra was analysed by the LINCOplex
technology and insulin by ELISA from the same cell culture
supernatant fractions, which were collected from three independent
experiments from three donors from three dishes for each experiment.
Data are shown as means of insulin divided by corresponding insulin
content±SE and normalised to control conditions at 5.5 mmol/l
glucose (i only). e–i Values on x-axis are glucose (mmol/l). j The rise
in IL-1Ra was confirmed by a time-dependent experiment using
isolated human islets exposed to 11.1 and 33.3 mmol/l glucose and
0.5 mmol/l palmitate (NEFA) for 30 min to 24 h. Western blot analysis
was performed for IL-1Ra and β-actin as loading control on the same
blot. Representative blots from three experiments from three donors
are shown. *p<0.05 vs untreated control at 5.5 mmol/l glucose;
**p<0.05 vs islets treated with BzATP, 11.1 or 33.3 mmol/l glucose or
NEFA, respectively
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Diabetologia (2009) 52:1579–1588 1583capacity in response to the HFD. There was no significant
change in beta cell mass in the P2X7-KO mice fed the HFD
compared with the P2X7-KO-ND mice. Moreover, beta cell
mass was significantly decreased compared with the wild-
type mice, independent of the diet (1.5-fold with ND and
1.5-fold with HFD, p<0.0.01, Fig. 3f, g). This was
confirmed after 16 weeks of diet. We have previously
reported the tendency to beta cell apoptosis in mice after
12 weeks of HFD despite an increased beta cell mass at that
time point [8]. Here, we analysed beta cell mass after 12
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Fig. 3 P2X7-deficient mice have impaired glucose tolerance and beta
cell mass and function and do not adapt IL-1Ra secretion during a
high-fat diet. a Changes in body weight in response to the HFD were
measured every week during the study and results are shown from
WT-ND (black squares), WT-HFD (black triangles), P2X7-KO-ND
(white squares) and P2X7-KO-HFD (white triangles) mice from three
different studies (12 mice per group). b Blood glucose following i.p.
injection of glucose at 1 g/kg body weight are shown from WT-ND
(black squares), WT-HFD (black triangles), P2X7-KO-ND (white
squares) and P2X7-KO-HFD (white triangles) mice after 12 weeks of
treatment. c Serum insulin levels following i.p. injection of glucose at
1 g/kg body weight are shown from mice after 12 weeks of treatment;
open bars show levels at 0 min, solid bars show levels at 30 min. The
stimulatory index (d) denotes the ratio of stimulated and basal insulin
levels in WT (black bars) and P2X7-KO (white bars) mice. e Blood
glucose concentrations in mice undergoing an insulin tolerance test
after 12 weeks of treatment. Insulin was injected i.p. at a
concentration of 0.5 U/kg body weight; WT-ND (black squares),
WT-HFD (black triangles), P2X7-KO-ND (white squares) and P2X7-
KO-HFD (white triangles). f Immunostaining for insulin in green
(magnification ×125) shows disrupted islets in the P2X7-KO mice,
which was confirmed by analysis of beta cell mass (g) in tissue sections
spanning the width of the whole pancreas from (1) WT-ND and (2) WT-
HFD (black bars), (3) P2X7-KO-ND and (4) P2X7-KO-HFD (white
bars) mice after 12 and 16 weeks of diet (n=4 mice for each group).
Beta cell mass per pancreas was estimated as the product of the relative
cross-sectional area of beta cells (determined by quantification of the
cross-sectional area occupied by beta cells divided by the cross-
sectional area of total tissue) and the weight of the pancreas. h Analysis
of beta cell apoptosis by triple staining for TUNEL, insulin and DAPI (a
fluorescent stain that binds strongly to DNA) was performed on the
same pancreatic sections. Results are expressed as percentage of
TUNEL-positive beta cells±SE normalised to control ND islets. The
mean number of beta cells scored was 6,239±1,035 for each treatment
condition from six individual mice per treatment (solid bars represent
WT, open bars P2X7-KO mice). i Serum levels of IL-1Ra were
measured after 4, 8, 12 and 16 weeks of diet (black bars represent
WT, white bars P2X7-KO mice).
ap<0.05 between mice on ND and
HFD;
bp<0.05 between P2X7-KO and WT mice;
cp<0.05 GSIS:
30 min vs 0 min;
dp<0.05 beta cell mass: 16 weeks vs 12 weeks
1584 Diabetologia (2009) 52:1579–1588and 16 weeks of diet. In contrast to 12 weeks, there was no
increase in beta cell mass in wild-type mice fed an HFD
compared with ND-fed animals after 16 weeks. To investi-
gate whether the changes in beta cell mass correlate with the
increased rate of apoptosis, we analysed TUNEL-positive
beta cells in pancreatic sections. After 16 weeks of diet, we
observed a clear increase in beta cell apoptosis in the control
HFDgroup.ThiswasfurtherincreasedintheP2X7-KO-HFD
mice (1.5-fold raise in apoptosis in the WT-HFD and 11.2-
fold in the P2X7-KO-HFD compared with ND controls,
p<0.01, Fig. 3h). As P2X7 regulates IL-1Ra secretion, we
tested whether IL-1Ra levels are altered in P2X7-KO mice.
The serum concentration of IL-1Ra was measured in WT
and P2X7-KO mice during the 16 weeks of HFD feeding. In
WT-ND mice, IL-1Ra levels were unchanged during the
experiment. IL-1Ra levels were significantly lower in P2X7-
KO-ND mice at 8, 12 and 16 weeks. Interestingly, after
4 weeks of diet, IL-1Ra increased 2.2-fold in the WT-HFD
mice; these high levels were maintained at 8 weeks (1.9-
fold compared with WT) and time-dependently decreased
again after 12 and 16 weeks of diet (1.5-fold and 2.4-fold
decrease from 8 weeks, respectively). After 16 weeks, IL-
1Ra levels with HFD were lower than with the ND (2.6-fold
decrease), which correlates with the changes in beta cell
mass. P2X7-KO mice, which had beta cells unable to
compensate via increasing beta cell mass, had no adaptive
increase in IL-1Ra levels (Fig. 3i). We have also measured
IL-1β serum levels together with IL-1Ra in the mouse
studies. Unfortunately, the levels were very low and mostly
under the lower level of the ELISA kit. Positive IL-1β
readings were found for some but not all samples from the
HFD-fed control mice at 12 and 16 weeks of diet, but none
were found in the ND or P2X7-KO mice, making statistical
data analysis not possible.
Isolated islets from P2X7-deficient mice display a defect
in insulin, IL-1Ra and IL-1β secretion As we observed
impaired glucose tolerance and survival in the P2X7-
deficient mice in vivo, we investigated whether impaired
beta cell insulin secretion could explain this effect. Islets
were isolated from all four treatment groups and insulin
secretion into the culture medium was measured. Acute
glucose-stimulated insulin secretion was abolished in islets
derived from wild-type mice fed a high-fat diet and was
further impaired in P2X7-KO-HFD mice (Fig. 4a). The
stimulatory index (the ratio of stimulated to basal insulin
secretion) was decreased 1.2-fold in the P2X7-KO-ND
mice, 2.4-fold in the WT-HFD mice and 3.4-fold in the
P2X7-KO-HFD mice compared with WT-ND control mice
(Fig. 4b). These data confirm the impaired beta cell
function in P2X7-KO mice from our in vivo studies on
the level of isolated islets. We then incubated the islets for
8 h at 33.3 mmol/l glucose or 0.5 mmol/l palmitate. As
expected, glucose and palmitate increased insulin secretion
in the wild-type islets. In contrast, islets from P2X7-KO
mice did not increase insulin secretion in response to the
stimulation (Fig. 4c). These data confirm the lack of
stimulation of insulin secretion in the P2X7-KO mice.
Under the same culture conditions, 72 h incubation of islets
with 0.5 mmol/l palmitate increased IL-1Ra as well as
IL-1β secretion from the wild-type but not the P2X7-KO
islets (Fig. 4d).
Discussion
The present study shows that P2X7 is produced in human
islets in the beta cell and is regulated during the progression
of type 2 diabetes. In human obesity, P2X7 is produced in
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Fig. 4 Isolated islets from P2X7-deficient mice display a defect in
insulin secretion. a, b For GSIS experiments, islets from all four
treatment groups (WT-ND, WT-HFD, P2X7-KO-ND and P2X7-KO-
HFD) were isolated after 12 weeks of diet and pre-cultured for 24 h on
dishes coated with extracellular matrix. a Glucose-stimulated insulin
secretion of islets. Basal (white bars) and stimulated (black bars)
insulin secretion during successive 1 h incubations at 2.8 mmol/l
(basal) and 16.7 mmol/l (stimulated) glucose divided by the
corresponding insulin content and expressed as means±SE, normal-
ised to control conditions at 11.1 mmol/l glucose. b The stimulatory
index denotes the ratio between stimulated and basal values of insulin
secretion. The assay was performed in triplicate with samples from
four individual mice (black bars represent WT, white bars P2X7-KO
mice). c Chronic insulin secretion over 8 h from islets isolated from
ND-fed WT (black bars) and P2X7-KO (white bars) mice exposed to
11.1 or 33.3 mmol/l glucose, or 11.1 mmol/l glucose and 0.5 mmol/l
palmitate (NEFA). Values on x-axis shown glucose (mmol/l). Glucose
and palmitate stimulated insulin secretion in the wild-type but not in
the P2X7-deficient islets. d IL-1Ra and IL-1β secretion from the
same islets after 72 h of treatment. Values on x-axis shown glucose
(mmol/l).
ap<0.05 GSIS: stimulated vs basal glucose;
bp<0.05
between ND- and HFD-treated mice;
cp<0.05 between P2X7-KO
and WT mice;
dp<0.05 treated (33.3 mmol/l glucose or NEFA) vs
untreated control
Diabetologia (2009) 52:1579–1588 1585large amounts, but is downregulated in pancreases obtained
from patients with type 2 diabetes, in lean as well as in
obese individuals. These data suggest that P2X7 plays an
important role in beta cell compensation. This is confirmed
in our subsequent studies using P2X7-KO mice. These mice
show impaired glucose tolerance and glucose-stimulated
insulin secretion together with an increased number of
apoptotic beta cells, which leads to a decrease in beta cell
mass. When P2X7-KO mice were challenged with a diet
enriched with fat and sucrose, they became severely glucose
intolerant and were completely unable to upregulate insulin
secretion inresponsetoglucoseduringanIPGTTinvivoora
GSIS assay in vitro. Although they had increased basal
insulin levels, which indicate an attempt to adapt for the
higher insulin demand, they were unable to compensate by
increasing beta cell mass during the diet. Beta cell mass
adaptation is an important mechanism to maintain normo-
glycaemia in obese insulin-resistant individuals, in whom
beta cell mass is almost doubled compared with lean
individuals [31]. Similar increases in beta cell mass in
diet-induced obesity were measured in mice using a diet
enriched with fat in a previous [32] or the present study.
Interestingly, the high-fat/high-sucrose ‘Surwit diet’ induces
an early reduction in beta cell proliferation at a time point
when beta cell mass is still increased [8], indicating a
development towards fewer cells. This tendency is substan-
tiated in the present study, where we show a decrease in
beta cell mass with time together with an induction of
beta cell apoptosis after 16 weeks of diet. In comparison,
P2X7-KO mice show a higher apoptosis rate under the ND
as well as under the HFD. The increase in basal insulin
levels in response to the diet together with a defect in the
compensation of beta cell mass indicates that, despite the
lower beta cell mass, high amounts of insulin can be
secreted. However, the functional failure is apparent in the
abolished response to glucose stimulation. A complete loss
of P2X7 was also observed in the NOD mouse with
manifest diabetes [33].
Little is known about the purinergic receptor family in
the beta cell and the effects on insulin release are
controversial. A low concentration of ATP stimulates
insulin secretion via the metabotropic purinergic receptor
subtype P2Y rather than via P2X receptors (the ionotropic
selective cation channel receptors) [34]. P2X7 was found in
rat alpha but not beta cells [33], its production in human
islets has not been studied before. Here, we show clearly
the production and regulation of P2X7 in the beta cell.
Fibroblasts from donors with type 2 diabetes have
increased P2X7-mediated responses compared with non-
diabetic donors, but levels of P2X7 were unchanged [24]. In
contrast, we report here a decrease in the level of P2X7 in
beta cells in type 2 diabetes. Consistent with the results
from fibroblasts, P2X7 activation was enhanced in isolated
islets by a diabetic milieu (high glucose and palmitic acid),
an effect prevented by P2X7 inhibition. High glucose
induces caspase 3 activation in beta cells as well as in
fibroblasts. It is possible that beta cell P2X7 receptors are
activated and produced in high numbers at a time when
IL-1Ra is highly secreted (e.g. in obesity) and when
diabetes develops, levels are lowered in specific cells.
Our in vitro studies on isolated islets show that P2X7 is
directly involved in insulin secretion. Activation of P2X7
by BzATP (which specifically targets P2X7 receptors [27,
35, 36]) or acute stimulation of insulin secretion by glucose
or palmitic acid for 1 h resulted in insulin release that was
partially inhibited by two P2X7 inhibitors.
Although secretory pathways of insulin and IL-1Ra are
distinct, one possible common step could be the calcium
exchange; activation of P2X7 increases intracellular calcium
levels by calcium influx from the extracellular space. This
leads to activation of the leaderless IL-1Ra-releasing
pathway through pore formation. Increased intracellular
calcium levels would also be a trigger for exocytosis of
insulin-containing secretory granules.
High glucose can also activate P2X7 in fibroblasts [37].
In parallel, BzATP, glucose and palmitic acid induced short-
term secretion of IL-1Ra, which was also inhibited by
KN-62. Apyrase, a less specific P2X7 inhibitor that affects
the ligands of all P2X7 receptors, showed similarities to the
specific P2X7 inhibitor KN-62 in blocking the effect of
BzATP on islets, suggesting that P2X7 is mainly activated
by glucose and palmitic acid in islets.
Intracellular IL-1Ra has no signal peptide. A possible
mechanism for release of intracellular IL-1Ra from the cells
to bind to IL-1R1 is through vesicle shedding, which occurs
through activation of the P2X7 by ATP [38]. Our data
indicate that IL-1Ra secretion is an ATP-dependent process
that requires P2X7 activation. This may be how intracellular
IL-1Ra, as well as IL-1β, is released from beta cells. Similar
results are obtained from macrophages and endothelial cells,
demonstrating that intracellular IL-1Ra and IL-1β are
secreted by an extracellular ATP-dependent mechanism
involving P2X7 activation [14]. We hypothesised that the
balance of IL-1β and IL-1Ra is crucial for the onset of
diabetes. P2X7 receptors have a dual role in this system:
they mediate the release of both pro-inflammatory IL-1β
and anti-inflammatory IL-1Ra. From in vitro experiments
weknow that an excess of 10-to 1,000-foldIL-1Ra isneeded
to inhibit the IL-1β effects, dependent on the exposure time
[4, 9]. Βeta cell dysfunction and increased apoptosis may
occur rapidly when IL-1Ra levels are decreased.
Corresponding with the levels of P2X7, increased IL-1Ra
serum levels correlate with obesity and insulin resistance
[39–42], whereas IL-1Ra is decreased in type 2 diabetes
[43]. Recent results from the Whitehall II study show that
IL-1Ra levels are increased before the onset of type 2
1586 Diabetologia (2009) 52:1579–1588diabetes [44], which is consistent with our findings in mice
fed with an HFD. The increase in IL-1Ra could be an attempt
by the body to counteract the deleterious effects of IL-1β and
to preserve beta cell survival, insulin secretion and insulin
sensitivity. In contrast, it has been speculated that increased
IL-1Ra could have an additional metabolic effect that leads to
insulinresistance.Thisisnotsupportedbyourresults,asdaily
IL-1Ra injections over 12 weeks did not impair insulin
sensitivity in C57Bl/6 mice in a previous study [8], and
increased IL-1Ra levels did not lead to changes in insulin
sensitivity in the present study. As shown by the bell-shaped
curve in Fig. 3i, decreased IL-1Ra levels occurred together
with the increase in beta cell apoptosis and the development
of diabetes in our study. Itwillnowbeimportanttodetermine
whether long-standing type 2 diabetes leads to decreased IL-
1Ra levels in humans in a follow-up study.
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